John Maraganore

Biography

 Since 2002, Dr. John Maraganore has served as the CEO and a Director of Alnylam. Prior to Alnylam, Dr. Maraganore served as an officer and a member of the management team for Millennium Pharmaceuticals, Inc. He was previously Vice President, Strategic Planning and M&A and, prior to that, he was General Manager of Millennium BioTherapeutics, Inc., a former subsidiary of Millennium. Before Millennium he served as Director of Molecular Biology and Director of Market and Business Development at Biogen, Inc. At Biogen, Dr. Maraganore invented and led the discovery and development of ANGIOMAX® (bivalirudin) for injection, formerly HIRULOGTM and currently marketed by The Medicines Company. Prior to Biogen, Dr. Maraganore was a scientist at ZymoGenetics, Inc., and the Upjohn Company. Dr. Maraganore received his MS and PhD in biochemistry and molecular biology at the University of Chicago. He is a Director for bluebird bio, Inc., and is the Chair of the Board for Agios Pharmaceuticals. Dr. Maraganore is Chair of the Biotechnology Industry Organization (BIO) Board, and is a member of the BIO Executive Committee.

Research Interest

Translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of patients who have limited or inadequate treatment options